Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI)
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
In the setting of reperfusion therapy in an acute myocardial infarction using primary
percutaneous intervention (PCI), the body's own inflammatory system involving the complement
cascade may be harmful. This study will test the safety and efficacy of a novel complement
inhibitor, pexelizumab to reduce mortality at 30 days.